Q-omics provides the consensus-scored EEF1DP5 profile across patient tissues and cancer cell-line models. EEF1DP5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EEF1DP5 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, EEF1DP5 RNA expression shows 8,139 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where EEF1DP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EEF1DP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EEF1DP5 survival associations across molecular data types. EEF1DP5 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EEF1DP5 RNA expression–survival associations across cancer types. High EEF1DP5 expression shows unfavorable associations in KIRC, ACC and LIHC, but favorable associations in GBM, ESCA and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for EEF1DP5 RNA expression.
This table summarizes EEF1DP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for EEF1DP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EEF1DP5 shows lower tumor expression in BRCA and higher tumor expression in COAD, HNSC and LUSC. The BRCA box plot shows higher EEF1DP5 RNA expression in normal versus tumor tissue (log2 FC = −0.725, t-test p < 0.001).
This table shows molecular features associated with EEF1DP5 in patient tissues and cancer cell lines. In patient samples, EEF1DP5 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
